Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-154.65M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.83 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -57.97% |
| Return on Assets (Trailing 12 Months) | -54.15% |
| Current Ratio (Most Recent Fiscal Quarter) | 34.46 |
| Quick Ratio (Most Recent Fiscal Quarter) | 34.46 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.18 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.23 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.85 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.29 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.24 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 88.41M |
| Free Float | 71.66M |
| Market Capitalization | $2.26B |
| Average Volume (Last 20 Days) | 0.78M |
| Beta (Past 60 Months) | 0.68 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 18.94% |
| Percentage Held By Institutions (Latest 13F Reports) | 84.46% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |